<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6673">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076503</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1513</org_study_id>
    <nct_id>NCT02076503</nct_id>
  </id_info>
  <brief_title>Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status</brief_title>
  <official_title>Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment,
      accurate staging of the disease at the time point of diagnosis is important. The objective
      of this study is to evaluate the diagnostic potential of a combined PET/MR examination for
      risk assessment and detection of lymph node metastases. The overall aim of the project is to
      improve the investigators ability to provide individually tailored treatment to prostate
      cancer patients.

      The study will include 32 men with high-risk prostate cancer, who are eligible for radical
      prostatectomy. Informed consent is a requirement for inclusion in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Positive and negative predictive value of 18FACBC PET/MR for detection of lymph node metastases</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Findings on 18FACBC PET/MR images will be compared to histopathology, which is considered the gold standard for evaluation of pelvic lymph node metastases</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET-MR 18f-FACBC</intervention_name>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>histology (gold standard)</intervention_name>
    <description>histopathological classification of co-located dissected lymph nodes</description>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-risk prostate cancer according to  EAU guidelines (Gleason score ≥8 and/or PSA
             ≥20 ng/ml and/or ≥ cT3a cancer)

          -  Eligibility for the surgical procedure (radical prostatectomy and bilateral pelvic
             lymph node resection)

        Exclusion Criteria:

          -  Previous treatment (for example TURP or hormone therapy)

          -  Contraindication for the PET/MR examination (including, but not limited to:
             pacemaker, aneurysm clips, reduced renal function, metal implants, claustrophobia)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Angelsen, prof</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ola Dalsegg Saether, MD</last_name>
    <phone>+47 73868370</phone>
    <email>ola.d.sether@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tone F Bathen, PhD prof</last_name>
    <email>tone.f.bathen@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept Urologic Surgery, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Dalsegg Saether, MD</last_name>
      <phone>+47 73868370</phone>
      <email>ola.d.sether@ntnu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm Staging</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>1-amino-3-fluorocyclobutane-1-carboxylic acid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
